Dr. Maggie L. DiNome

Dr. Maggie DiNome meets every new patient at Duke Cancer Institute with the calm assurance that follows decades of breast-cancer surgery and service-line leadership. As Chief of Breast Surgery and medical director for community programs in Wake County, she convenes radiologists, medical oncologists, genetic counselors, and rehabilitation specialists in a single case-planning session before the first clinic visit. Digital dashboards display tumor imaging beside genomic results and personal goals such as preserving upper-body strength for childcare or returning to artistic work, allowing the opening plan to balance oncologic completeness with quality-of-life priorities. Clinic coordinators schedule mammography, core-needle biopsy, anesthesia evaluation, and lymphedema education on the same morning, while nurse navigators translate clinical jargon into concise explanations that show, for instance, how sentinel lymph-node mapping can spare full axillary dissection without compromising staging accuracy. Weekly quality rounds compare margin status, readmission frequency, and time to adjuvant therapy; immediate adjustments—like earlier speech-therapy consults or same-day pathology reads—follow when metrics drift. Patients therefore move through a pathway that feels orderly, transparent, and responsive, confident that every specialist understands the whole picture and remains reachable for questions. 

Research occupies equal footing in Dr. DiNome’s career, shaping how operations evolve for future families. Her clinical studies test de-escalation of axillary surgery in node-positive breast cancer, showing that selective omission of completion lymph-node dissection can control disease while reducing numbness and shoulder stiffness. A parallel laboratory program explores epigenetic reprogramming in hormone-receptor-negative tumors, measuring how DNA-methylation inhibitors might restore estrogen sensitivity and open endocrine-therapy options. Surgical specimens reach the biobank minutes after excision, where single-cell sequencing maps resistant subclones and sends alerts back to tumor boards that guide postoperative therapy. Collaborations with bioinformaticians generate risk calculators that stratify patients for observation versus intervention, and partnerships with pharmacologists refine short-course neoadjuvant regimens that shrink tumors enough to conserve the nipple-areolar complex. This seamless bench-to-bedside loop places tomorrow’s strategies into today’s consent discussions, giving patients access to innovations once considered experimental while safeguarding safety through constant data review.

Education and outreach extend Dr. DiNome’s influence far beyond the operating suite. As a professor of surgery, she mentors residents with simulation curricula that pair three-dimensional breast models with real-time commentary on oncoplastic design and lymph-sparing dissection. She publishes video-based performance metrics in open-access forums, enabling programs worldwide to benchmark progress. Community webinars delivered in English and Spanish explain high-risk screening schedules, genetic testing for BRCA and PALB2, and telehealth follow-up, ensuring that accurate information reaches households without specialty clinics. Her social-media updates distill conference abstracts into plain language within hours, while podcasts featuring survivor voices remind clinicians that statistics represent lived experience. Nationally, she co-authors position papers on racial disparities in breast-cancer outcomes, advocating insurer coverage for molecular profiling and reconstruction regardless of zip code. Regional outreach caravans pair portable ultrasound with on-site navigation, catching abnormalities early and guiding women into streamlined care pathways. Families therefore meet a surgeon who not only operates with precision but also shapes the landscape in which that precision becomes possible.